Lifecore Biomedical Inc
Open
SectorConsumer defensive
4.07 -1.21
Overview
Share price change
24h
Min
3.96
Max
4.13
Income | 9.8M -6.2M |
|---|---|
Sales | 11M 34M |
Profit margin | -18.017 |
Employees | 382 |
Next Earnings | 10 gru 2026 |
|---|
Market Cap | -20M 140M |
|---|---|
Previous open | 5.28 |
Previous close | 4.07 |
News Sentiment
By Acuity
50%
50%
56 / 130 Ranking in Consumer defensive
Lifecore Biomedical Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Lifecore Biomedical Inc Forecast
Sentiment
By Acuity
56 / 130 Ranking in Consumer defensive
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Lifecore Biomedical Inc
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.